Mitsubishi Chemical to negotiate with Bain to sell drug unit

Deal for Mitsubishi Tanabe Pharma could reach more than $3.2bn

20250120 bain

Bain Capital and Mitsubishi Chemical Group are in talks over Tanabe Phama. (Source photos by Nikkei)

Nikkei staff writers

TOKYO -- Japan's Mitsubishi Chemical Group has granted a first-refusal right to U.S. investment fund Bain Capital for the purchase of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma, Nikkei has learned.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.